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Abstract
Several patient-reported outcome measures have been developed to assess health status in pulmonary arterial hypertension. The
required change in instrument scores needed, to be seen as meaningful to the individual, however remain unknown. We sought to
identify minimal clinically important differences in the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) and to
validate these against objective markers of functional capacity. Minimal clinically important differences were established from a
discovery cohort (n¼ 129) of consecutive incident cases of idiopathic pulmonary arterial hypertension with CAMPHOR scores
recorded at treatment-naı̈ve baseline and 4–12 months following pulmonary arterial hypertension therapy. An independent
validation cohort (n¼ 87) was used to verify minimal clinically important differences. Concurrent measures of functional capacity
relative to CAMPHOR scores were collected. Minimal clinically important differences were derived using anchor- and
distributional-based approaches. In the discovery cohort, mean (SD) was 54.4 (16.4) years and 64% were female. Most patients
(63%) were treated with sequential pulmonary arterial hypertension therapy. Baseline CAMPHOR scores were: Symptoms, 12 (7);
Activity, 12 (7) and quality of life, 10 (7). Pulmonary arterial hypertension treatment resulted in significant improvements in
CAMPHOR scores (p< 0.05). CAMPHOR minimal clinically important differences averaged across methods for health status
improvement were: Symptoms, –4 points; Activity, –4 points and quality of life –3 points. CAMPHOR Activity score change
minimal clinically important difference was associated with significantly greater improvement in six-minute walk distance, in both
discovery and validation populations. In conclusion, CAMPHOR scores are responsive to pulmonary arterial hypertension treat-
ment. Minimal clinically important differences in pulmonary hypertension-specific scales may provide useful insights into treatment
response in future clinical trials.
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Introduction
Pulmonary arterial hypertension (PAH) is a rare disorder
characterised by a progressive rise in mean pulmonary
artery pressure and pulmonary vascular resistance, ulti-
mately resulting in right heart failure and death.1 PAH
may present with a range of non-specific, yet debilitating
symptoms which can affect health-related quality of life
(HRQoL).1–3 As there is presently no cure for PAH, phar-
macotherapy remains the mainstay of treatment with the
aim of slowing disease progression and alleviating symp-
toms.1 Despite recent treatment advancements improving
PAH survival, symptomatic burden remains high.4–8
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Conventionally, establishing drug efficacy in PAH clini-
cal trials has relied upon observed changes in functional
status and capacity.4 It has not until relatively recently
that composite morbidity and mortality end-points have
been employed in event-driven trials, as highlighted by
Sitbon et al.9 Whether selected trial end-points are relevant
to the individual, however, remains unknown. As a result,
there is an increasing awareness of the need for patient-
reported outcomes (PROs) to be incorporated as secondary
end-points in PAH clinical trials.10
Despite this, PROs continue to remain under-utilised.
This, in part, is because changes in HRQoL measures
have been more modest than objective end-points such
as six-minute walk distance11,12 or pulmonary haemody-
namics.4 Generic measures of HRQoL (e.g. SF-36) conven-
tionally used in such trials, however, may lack sensitivity
to detect change in specific disease processes such as
PAH.13 To address this, a number of pulmonary
hypertension-specific HRQoL instruments have been devel-
oped and validated: Cambridge Pulmonary Hypertension
Outcome Review (CAMPHOR),14 EmPHasis-10,2
Living with Pulmonary Hypertension15 and Pulmonary
Arterial Hypertension-Symptoms and Impact (PAH-
SYMPACT).16 Such disease-specific PROs have been
shown to track functional status, clinical deterioration and
prognosis in PAH.12,17 The magnitude of improvement in
these measures needed to be seen as meaningful by the indi-
vidual, or the Minimal Clinically Important Difference
(MCID), however, are unknown. This is of importance as
even in the absence of statistically significant changes in
PRO end-points, interventions may still be of relevance to
the patient. Furthermore, knowledge of a measure’s MCID
provides useful information regarding longitudinal changes
in PROs and the monitoring of individual patient’s clinical
progression.
Although the MCID has become a standard approach
in the interpretation of the clinical relevance of changes
in PROs, there remains no ‘gold-standard’ for MCID esti-
mation and methodological approaches remain much
debated.18 Broadly, MCIDs may be estimated using distri-
butional- or anchor-based approaches.19 Distributional
methods rely on the statistical characteristics of scores
around the mean (e.g. standard deviation (SD)) whilst
anchor-based methods link changes in PRO scores to a
second external measure of change, or the anchor, and are
therefore presumed to be sample independent. Global
assessments of health change are most frequently employed
as anchors in MCID estimations and enable the direct asso-
ciation of PRO score change to a patient’s preferences and
values.20 They are, however, subject to recall bias.21 Given
limitations in both distributional and anchor-based MCID
methods, conventionally both methods are employed with
MCIDs typically reported as the mean of combined
estimates.22
We provide the first estimation of a MCID in a pulmo-
nary hypertension-specific PRO measure (CAMPHOR)
using both distributional- and anchor-based methods.
Furthermore, we demonstrate validation of these estimates
using objective markers of PAH severity.
Methods
All incident and prevalent cases of idiopathic pulmonary
arterial hypertension (IPAH) between January 2006 and
June 2018 were eligible for inclusion. Follow-up was includ-
ed until 1 June 2019. All patients were age >18 years at the
time of diagnostic right heart catheterisation. IPAH diag-
nosis and treatment was as per international guideline rec-
ommendations at the time of diagnosis.1,23,24 Clinical data
were collected prospectively into a dedicated pulmonary
vascular diseases database.
The discovery cohort was comprised of all incident cases
of IPAH with CAMPHOR scores available at treatment-
naı̈ve baseline and within 4–12 months following the initia-
tion of PAH-specific therapy. A minimum follow-up of four
months was chosen as this reflects the upper limit of the 12–
16 week end-point historically employed for outcome
assessment in PAH clinical trials.9 A maximum follow-up
interval of 12 months was chosen as beyond this, it is
increasingly difficult to attribute changes directly related
to the initiation of drug therapy.
The validation dataset was formed of incident and prev-
alent cases of IPAH not included in the discovery cohort
with at least two serial CAMPHOR scores recorded at any
time point until end of follow-up. In the main, individuals in
the validation cohort were prevalent cases diagnosed before
the routine clinical use of CAMPHOR in 2006. Baseline
pre-treatment PRO scores were therefore unavailable for
this group. A minimum time period of six weeks between
CAMPHOR scores was set to limit the testing effect of
repeated measures completed within a short time-frame.
No maximum time limit between CAMPHOR completion
dates was set for the validation cohort. Prevalent cases
underwent clinical review every six months as standard
with CAMPHOR questionnaires completed at each visit.
New York Heart Association (NYHA) functional class,
six-minute walk distance (6MWD) and N-Terminal pro-
Brain Natriuretic Peptide (NT-proBNP) levels concurrent
to CAMPHOR completion were recorded where available.
CAMPHOR questionnaire
The CAMPHOR questionnaire contains 65 items measur-
ing; Symptoms (25 questions), Activity (15 questions) and
quality of life (25 questions). Symptoms and quality of life
are both scored out of 25, and activity out of 30. Scores are
negatively weighted so that a higher score reflects worse
quality of life and greater functional limitation.14
At the beginning of the CAMPHOR questionnaire,
patients are also prompted to provide responses to two
2 | Establishing a MCID for CAMPHOR in IPAH Bunclark et al.
global ratings of health status. One question assesses cur-
rent health status with available responses of poor/fair/
good/excellent, and the other, change in health status rela-
tive to last clinical review with available responses ranging
from ‘significantly worse’ to ‘significantly better’ on a seven-
point scale.
Statistical analysis
Statistical analysis was performed using R version 3.6.1.25
Data averages for continuous variables were reported as
mean (SD) and categorical variables as n (percentage of
total). As CAMPHOR scores are ordinal, values were
rounded to the nearest whole number. Paired t-tests were
used to compare CAMPHOR scores at baseline and post-
treatment. Reported p-values were adjusted for multiple
comparisons by false discovery rate at 5%, where necessary.
Survival was calculated using a censoring date of last clinic
visit or 1 June 2019, whichever was later. The National
Health Service summary care record tracking system was
used to ascertain survival status (searched 1 June 2019).
Cox Proportional Hazards models were used to assess asso-
ciations between baseline characteristics and five-year
survival.
MCID estimation
In the absence of gold-standard methodology, MCID esti-
mates were based upon prevailing methodological
approaches reported in systematic review22 and expert
opinion.18–21
Distributional-based MCID estimation. MCIDs were estimated
using three distributional-based approaches:
SD: the SD represents the variation among a group of
scores. As 0.5-SD is widely accepted as corresponding to the
MCID,26 this statistic was adopted for the purposes of
MCID estimation in this study. The SD of all scores for
each of the three CAMPHOR subdomains was divided by
2 to derive 0.5 SD.
Effect size (ES): ES is a standardised measure of change
which can be expressed mathematically as27,28
ES ¼ m2 m1
d1
where m2¼ group mean at follow-up
m1¼ group mean at baseline
d1¼ group standard deviation at baseline
MCIDs expressed as ES reduce bias which mainly result
from dependency on baseline scores.22 As the MCID of a
scale is generally considered to correspond to a small ES
(0.2), the above formula was re-arranged so that the ES
MCID was attained by multiplying the SD of baseline
scores by 0.2.29,30
Standard error of measurement (SEM): the SEM for
each of the three CAMPHOR subscales was derived using
the calculation28
SEM ¼ rx1 rxx
where rx¼ the standard deviation at baseline
rxx¼ the reliability of the HRQoL measure
Test–retest reliability coefficients for each of the three
CAMPHOR subscales have been established and validated:
symptoms, 0.92; activities, 0.86 and quality of life (QoL),
0.92.14 A number of thresholds have been suggested (1-,
1.96- and 2-SEM) when employing the SEM in MCID esti-
mation.31–33 As the most widely validated is 1-SEM, this
was used for the purposes of this study.31
Anchor-based MCID estimation. Anchor-based MCID estima-
tions were attained using within-person and sensitivity-
based approaches using methods similar to Van Der Roer
et al.:34
Within-person global ratings change: this is the first
and most widely used of the anchor-based MICID
approaches.20,22 It defines the MCID as ‘the change in
PRO scores of a group of patients selected according to
their answers to a global assessment scale’ which serves as
the anchor.20 A seven-point global rating of health status
change was utilised as an anchor for this study with avail-
able ratings of ‘very much worse’ (–3) to ‘very much better’
(þ3). The MCID was calculated as the mean score change
from baseline to post-treatment of those who reported
they were ‘moderately better’ (þ2) compared to initial base-
line review.
Sensitivity and specificity analysis: Receiver Operating
Curves (ROC) were used to determine the score change
from treatment-naı̈ve baseline to post-treatment with
equal sensitivity and specificity to discriminate between
‘improved’ and ‘unchanged’ patients. Improved patients
were those reporting a health status change of ‘moderately
better’ (þ2) or ‘very much better’ (þ3) compared to treat-
ment-naı̈ve baseline. Unchanged patients were those who
reported a health status change of ‘a little worse/better’
(1) or ‘no change’ (0) from baseline.
Results
There were 184 consecutive incident cases of IPAH during
the study period, of whom 129 patients had available pre-
and post-PAH treatment CAMPHOR scores and formed
the discovery cohort. The characteristics of incident IPAH
patients included and excluded from the discovery cohort
did not differ (online Appendix Table 1).
Discovery cohort patient demographics and characteris-
tics at treatment-naive baseline and post PAH treatment
are outlined in Table 1. Mean (SD) age was 54.4 (16.4)
years and 64% were female. Three individuals were
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vasoresponders to nitric oxide. The majority of patients
(63%) were treated following PAH diagnosis with oral
monotherapy (sequential therapy). Twenty-four patients
(22%) were treated with upfront parenteral prostanoid ther-
apy. In the five years following IPAH diagnosis, 32 patients
in the discovery cohort died and one underwent lung
transplantation.
CAMPHOR scores at treatment-naı̈ve baseline were
mean (SD): Symptoms, 12 (7); Activity, 12 (7) and QoL,
10 (7). Baseline CAMPHOR scores were poorly correlated
with pre-PAH treatment haemodynamics (Symptoms,
r¼ 0.10–0.33; Activity, r¼ 0.04–0.30; QoL, r¼ 0.02–0.23)
but were moderately correlated with 6MWD (Symptoms,
r¼ –0.54; Activity, r¼ –0.70; QoL, r¼ –0.55, p< 0.001; all,
Fig. 1). Discovery cohort 1-, 3- and 5-year survival was
98.4%, 83.2% and 70.1%. Mortality was associated with
a higher activity score, older age and lower six-minute
walk distance at PAH diagnosis as well as female sex
(Table 2).
PAH therapy was associated with a significant improve-
ment in CAMPHOR subdomain scores: Symptoms:
p¼ 0.001; Activity, p¼ 0.041; QoL, p¼ 0.009 (Table 1).
Significant gains were also seen in NYHA functional
class, 6MWD and plasma NT-proBNP level with treatment
(p< 0.01; all, Table 1). Change in CAMPHOR score was
weakly correlated with baseline score (i.e. higher baseline
score associated with greatest score reduction): Symptoms,
(Pearson) r¼ –0.34; Activities, r¼ –0.31 and QoL r¼ – 0.43
(p< 0.001; all).
Global ratings of health
Patient-reported global health status at baseline (n¼ 108)
was: Poor (n (%), 26 (24%); Fair, 44 (41%); Good, 34
(31%) and Very Good, 4 (4%). The proportion of patients
reporting a Good or Very Good health status increased
post-PAH treatment (n¼ 114): Poor (n (%)), 13 (11%),
Fair, 37 (32%), Good, 47 (41%) and Very Good, 17
(15%; p¼ 0.002). Global health ratings were appropriately
discriminated by CAMPHOR subscale scores: Symptoms,
p< 0.001; Activity, p< 0.001; QoL, p¼ 0.012 (online
Appendix Table 2).
A total of 117 individuals provided global ratings of
health change following PAH treatment. The seven poten-
tial responses of ‘very much worse’ to ‘very much better’
Table 1. Patient demographics and characteristics at treatment-naı̈ve baseline and following PAH treatment (n¼ 129).
n Treatment-naı̈ve baseline n Post-PAH treatment Adjusted p
Age, years 129 54.4 (16.4)
Sex, female % 129 63.9
Transfer factor, % pred 83 66 (30)
Vasorespondera, n (%) 129 3 (2)
PAH therapy, n (%) 109
Monotherapy 69 (63)
Dual therapy 13 (12)
IV therapy 24 (22)
RAP, mmHg 109 11 (13)
Mean PAP, mmHg 109 52 (12)
PVR, dynes/s/cm-5 109 1304 (1030)
CO, l/min 109 3.6 (1.1)
NYHA class, n (%) 122 102
1 1 (1) 6 (6)
2 14 (11) 29 (29)
3 92 (75) 64 (63)
4 15 (12) 3 (3) 0.001
CAMPHOR score
Symptoms 129 12 (7) 129 10 (7) 0.001
Activity 129 12 (7) 129 11 (8) 0.041
Quality of life 129 10 (7) 129 9 (7) 0.009
6MWD, m 110 291 (123) 95 344 (145) 0.007
NTproBNP, pg/mlb 118 1154 (2286) 114 429 (1447) 0.001
Notes: Values are expressed as mean (standard deviation) unless otherwise specified. p-values were adjusted for multiple comparisons. Data were recorded closest
to the time of IPAH diagnostic right heart catheter and before PAH treatment with pulmonary vasodilators (treatment-naı̈ve baseline) and at 4–12 month clinical
review following the initiation of PAH therapy (post PAH treatment).
PAH: pulmonary arterial hypertension; RAP: right atrial pressure; PAP: pulmonary arterial pressure; PVR: pulmonary vascular resistance; CO: cardiac output;
NYHA: New York Heart Association functional class; CAMPHOR: Cambridge Pulmonary Hypertension Outcome Review questionnaire; 6MWD: six-minute walk
distance; NT-proBNP: N-Terminal pro-Brain Natriuretic Peptide.
aPositive response to vasoreactivity challenge with nitric oxide as defined by current international guideline.1
bValues expressed as median (interquartile range).
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were discriminated by CAMPHOR subscale scores
(p< 0.001, all; Table 3). Frequencies of reported change
are displayed in online Appendix Figure 1. Thirty-five indi-
viduals (30%) reported a change in health status of at least
‘moderately better’ with PAH treatment and were consid-
ered to have ‘improved’.
Anchor and distributional MCID estimates
Distributional MCIDs were calculated using 0.5SD, the ES
and SEM as described above. For the Symptoms domain,
distributional MCIDs were 4-points, 1-point and 2-points,
respectively; for the Activity domain: 4-points, 1-point and
3-points, respectively and for QoL: 4-points, 2-points and 2-
points (Table 4).
Anchor-based MCIDs generated from the mean change
in CAMPHOR score for those who reported feeling ‘mod-
erately better’ post PAH treatment were: Symptoms, –5
points; Activity, –4 points and QoL, –4 points and from
ROC thresholds: Symptoms, –6 points (Area Under
Receiver Operating Cure (AUROC) 0.79; 95% Confidence
Interval (CI): 0.70–0.88), Activity, –6 points (AUROC 0.73;
95% CI: 0.63–0.84) and QoL, –1 points (AUROC 0.80;
95% CI: 0.72–0.88).
Final MCID estimates derived by taking the mean of
distributional- and anchor-based results were: Symptoms,
4 points; Activity, 4 points and QoL, 3 points. MCIDs in
CAMPHOR subscale scores between treatment-naı̈ve base-
line and post-PAH treatment were achieved by 41 patients
(32%) for Symptoms, 39 patients (30%) for Activity and 47
patients (36%). Seventeen patients (13%) achieved the
MCID across all three scales.
MCID validation
MCIDs were first compared against objective markers of
PAH severity in the discovery cohort. The CAMPHOR
Activity domain had the strongest correlation with
6MWD (Pearson r¼ 0.70, p< 0.001). Those attaining the
Activity MCID had a greater change in 6MWD (82.3
(80.8) m versus 38.8 (75.3) m; p¼ 0.030) from a lower base-
line 6MWD (250 (108) versus 311(125) m; p¼ 0.015) than
those who did not. Activity MCID achievement was also
associated with a greater fall in NTproBNP level (–1094
(1948) versus –448 (1736) pg/ml) and an increased frequency
of NYHA functional class improvement (42% vs. 33%),
although these did not reach statistical significance
(p¼ 0.106 and p¼ 0.522, respectively).
Fig. 1. Correlation matrix for baseline CAMPHOR scores against
haemodynamic, age and functional status.
Positive correlations are displayed in blue and negative correlations in
red. Colour intensity and the size of the circle are proportional to the
correlation coefficients.
mpap: mean pulmonary artery pressure; rap: right atrial pressure
(mean); pvr: pulmonary vascular resistance; co: cardiac output;
6MWD: six-minute walk distance; QoL: quality of life.
Table 2. Cox proportional hazard model of survival from date of
IPAH diagnosis.
Units HR (95% CI) p Values
CAMPHOR
Symptoms 1 1.06 (1.00–1.12) NS
Activity 1 1.06 (1.01–1.11) 0.031
QoL 1 1.03 (0.98–1.09) NS
Age 10 1.32 (1.05–1.66) 0.019
Sex Female 2.26 (1.13–4.54) 0.021
6MWD 10 0.96 (0.93–0.99) 0.015
Haemodynamics
mPAP 1 0.97 (0.94–1.01) NS
PVR 1 1.00 (1.00–1.01) NS
Cardiac index 1 0.57 (0.31–1.05) NS
Notes: The association between baseline variables (treatment-naı̈ve) and long-
term survival was assessed. IPAH diagnosis date taken from time of diagnostic
right heart catheterisation.
CAMPHOR: Cambridge Pulmonary Hypertension Outcome Review; QoL:
quality of life; 6MWD: six-minute walk distance; mPAP: mean pulmonary artery
pressure; PVR: pulmonary vascular resistance; CI: confidence interval; HR:
hazard ratio.
Table 3. Change in CAMPHOR score for global ratings of health
status change with PAH treatment (n¼ 117).
n Symptoms Activity Quality of life
Very much worse 4 7 (5) 8 (5) 9 (7)
Moderately worse 8 3 (6) 3 (6) 4 (6)
A little worse 16 0 (4) –1 (4) 0 (4)
Not changed 31 –2 (4) –2 (4) –1 (5)
A little better 23 –1 (7) 0 (4) –1 (5)
Moderately better 18 –5 (5) –4 (5) –4 (5)
Very much better 17 –9 (6) –4 (6) –8 (6)
Notes: Values expressed as mean (standard deviation). Global health and
CAMPHOR score change at 4–12 month post PAH treatment review relative
to treatment-naive baseline.
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MCID estimates were further verified in a validation
dataset comprised of 1008 CAMPHOR observations with
contemporaneous 6MWD measurements across 87 incident
and prevalent cases of IPAH. Mean interval between obser-
vations was 188 days. The Activity scale again had the high-
est correlation with 6MWD: r¼ –0.58 (p< 0.001) of the
three CAMPHOR subdomains. There were 94 instances
of Activity MCID (–4 points) attainment between serial
CAMPHOR observations during the study period.
Change in 6MWD associated with Activity MCID attain-
ment was 31.4 (64) m compared to –4.6 (35) m for episodes
of Activity MCID non-attainment (p< 0.001).
Discussion
The symptomatic burden of PAH and its effects on HRQoL
are widely known.4–8,35 Changes in HRQoL in response to
PAH treatment in the ‘real world’ setting, however, remains
poorly understood. This is the first systematic study to
directly assess the impact of PAH therapy on HRQoL out-
side of the clinical trial setting using a PH-specific PRO
measure; CAMPHOR. We demonstrate significant
improvements in each of the three CAMPHOR subdomains
with PAH therapy, alongside improvements in objective
measures of PAH treatment response: functional class, exer-
cise capacity and NTproBNP level. Using distributional and
anchor-based methods, we propose minimum thresholds of
CAMPHOR score change deemed clinically relevant to
individuals with PAH, or the MCID. Attainment of the
Activity scale MCID (four-point change) was associated
with a significantly higher increase in exercise capacity in
both incident and prevalent population compared to those
who failed to achieve the required change.
As with previous studies utilising CAMPHOR, we
demonstrate moderate correlations between CAMPHOR
subdomains and exercise capacity;14 the Activity subscale
having the strongest relationship with six-minute walk dis-
tance (r¼ 0.70). Correlations compare favourably with
those derived using generic (SF-36, r¼ 0.40–0.60) and
PH-specific (PAH-SYMPACT, r¼ 0.14–0.57) PRO meas-
ures and reinforce the CAMPHOR as an excellent surrogate
of functional limitation.36–38 Treatment-naive CAMPHOR
scores were weakly correlated with diagnostic
haemodynamics (r¼ 0.04–0.33) suggesting that factors
beyond PAH haemodynamic severity measured at rest influ-
ence symptomatic burden. To our knowledge, this is the
first study to relate haemodynamics to a pulmonary
hypertension-specific PRO and reinforces similar findings
from the use of generic-HRQoL measures.37
Whilst anecdotally, there is the perception that PAH
therapies improve patient’s HRQoL, there is limited ‘real
word’ data to support subjective physician experience.
Although PROs have been incorporated as secondary end-
points in PAH clinical trials, these have relied upon generic
HRQoL measures which may be less sensitive to change in
specific disease process such as PAH. This may at least
partly explain why only modest changes in PRO end-
points have been observed to-date.13 In this study, we dem-
onstrate the significant improvement in CAMPHOR scores
following initiation of PAH therapy (Symptoms: p¼ 0.001;
Activity, p¼ 0.041; QoL, p¼ 0.009). Furthermore, improve-
ments in CAMPHOR score tracked changes in objective
measures of treatment response including: six-minute walk
distance, NYHA functional class and plasma NTproBNP
level, reflecting the ability of CAMPHOR scores to detect
change and be responsive over time.
Survival from PAH diagnosis was associated with lower
baseline CAMPHOR Activity score, younger age at diag-
nosis, female sex and greater exercise capacity. Whilst our
limited sample size precluded a robust evaluation of the
additional contribution of PROs to prognostication using
proposed risk stratification tools, the significance of base-
line CAMPHOR scores in predicting long-term survival
highlights the insights that can be gained simply from
patient perceptions alone.
In chronic diseases such as PAH where there is no ‘cure’,
understanding clinically important change to patients
becomes more relevant. To our knowledge, this is the first
study to quantify a MCID in IPAH for a disease-specific
PRO measure. Standardised methodology for MCID esti-
mation has yet to be determined. Both distributional and
anchor-based approaches have their limitations which have
been extensively discussed elsewhere.18,21 Methodology in
this study was based on prevailing consensus opinion. As
global ratings of health change are the most commonly used
measure when attempting to identify within patient change,
Table 4. CAMPHOR subscale MCID estimates for clinical improvement by distributional and anchor-based methods.
Symptoms Activity QoL
Distributional
0.5 SD 4 4 4
Effect size 1 1 2
SEM 2 3 2
Anchor-based
Mean (SD) change –5 (6) –4 (5) –4 (6)
Sensitivity analysis – 6 –6 –1
(AUROC, 95% CI) (0.79; 0.70–0.88) (0.73; 0.63–0.84) (0.80; 0.72–0.88)
SD: standard deviation; SEM: standard error of measurement; AUROC: Area under the Receiver Operating Curve; CI: confidence interval; QoL: quality of life.
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this approach was adopted for anchor-based
estimations.18,21,22
Across five methods (three distributional and two
anchor-based), MCIDs for improvement in CAMPHOR
were; Symptoms: –4 points, Activity: –4 points and QoL,
–3 points. A third of incident patients achieved an MCID in
at least one of the three CAMPHOR subdomains with PAH
therapy. Change in CAMPHOR Activity scale score that
was equivalent, or greater than, the MCID was associated
with a significantly greater increase in six-minute walk dis-
tance from diagnostic baseline compared to those who did
not attain the MCID threshold (82.3 m vs. 38.8 m; p¼ 0.03).
Greater improvements in NTproBNP levels and NYHA
functional class were also seen in those who attained the
MCID although these did not reach statistical significance.
As change in CAMPHOR score was only weakly associated
with baseline scores, MCID thresholds should be relevant
irrespective of the initial degree of HRQoL impairment.
The longitudinal relevance of CAMPHOR MCID esti-
mates was demonstrated in an extended validation cohort
comprised of 1008 instances of CAMPHOR score comple-
tion in 87 incident and prevalent cases of IPAH. Once
again, a change in CAMPHOR Activity score at least equiv-
alent to the MCID of –4 points between serial CAMPHOR
measures was associated with greater gains in six-minute
walk distance compared to individuals who did not report
a MCID threshold change (31.4 (64) m versus –4.6 (35) m).
This distance of 31 m associated with CAMPHOR Activity
MCID attainment compares favourably to direct estimates
of the MCID in 6MWD for PAH of 33 m, and reinforces
the utility of these values in determining relevant change at
the level of the individual.37 The validation of MCID esti-
mates in both incident and prevalent populations enables
not only a better understanding of the effects of intervention
at the cohort level (e.g. when submitted to clinical trials) but
provides useful insights when monitoring individual
patient’s progress.
Whilst this study has a number of strengths, we acknowl-
edge that although patient characteristics were similar to
those of well-published PAH cohorts, data from this study
originate from a single pulmonary hypertension centre and
may therefore be subject to bias. CAMPHOR has also
received criticism for being more time intensive than other
available pulmonary hypertension QOL measures, however
remains the most validated with adaption for use in, but not
limited to, the: United States,39 Australia/New Zealand,40
Portugal,41 Germany,42 Netherlands,43 Poland,44 Brazil,45
Croatia,46 French/English Canada47 and Columbia.48 This
provides plentiful opportunity for the external validation of
MCID estimates to assess their robustness which is unaf-
forded by other measures at present. Moreover,
CAMPHOR is the only clinically utilised measure inclusive
of a global assessment of health. As global assessments of
health change enable the direct association of PRO score
change to a patient’s preferences and values, the inclusion of
anchor-based methodology in any MCID estimation is gen-
erally considered mandatory.22
One further limitation to our study is the absence of a
gold standard methodology for MCID estimation. We have
however aligned our methodological approach to prevailing
consensus opinion and indeed have derived estimates using
approaches in excess of those seen in the majority of other
published MCID works, refining the accuracy of our esti-
mates to the best available.22 Further work is required to
determine universally accepted methods for MCID estima-
tion which may be of relevance to our work in the future.
In conclusion, we have established MCIDs for patient-
relevant clinical improvement in CAMPHOR subscale
scores and demonstrate the correlation of the CAMPHOR
Activity subscale to functional capacity. MCIDs in a
pulmonary hypertension-specific PRO measure provides
useful insights when monitoring individual patient’s prog-
ress and allows for a better understanding of the effects of
intervention at the cohort level (e.g. when submitted to clin-
ical trials).
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